Industry Focus
Healthcare: Johnson & Johnson Takes A Shot At Gilead Sciences
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:13:46
- Mas informaciones
Informações:
Sinopsis
Johnson & Johnson has inked a licensing deal with Achillion Pharmaceuticals that could threaten Gilead Sciences market share in hepatitis C someday. Motley Fool's Michael Douglass and Todd Campbell dig into the details of this deal to see if Gilead Sciences investors should worry.
